Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
May 22, 2017 12:42 pm UTC| Business
Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture 20% share of...
Meritage Homes Announces Offering of $300 Million of Senior Unsecured Notes Due 2027
May 22, 2017 12:37 pm UTC| Business
SCOTTSDALE, Ariz., May 22, 2017 -- Meritage Homes Corporation (NYSE:MTH), a leading U.S. homebuilder, today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal...
Meritage Homes Announces Offering of $300 Million of Senior Unsecured Notes Due 2027
May 22, 2017 12:38 pm UTC| Business
SCOTTSDALE, Ariz., May 22, 2017 -- Meritage Homes Corporation (NYSE:MTH), a leading U.S. homebuilder, today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal...
Diana Containerships Inc. Reports Financial Results for the First Quarter Ended March 31, 2017
May 22, 2017 12:36 pm UTC| Business
ATHENS, Greece, May 22, 2017 -- Diana Containerships Inc. (NASDAQ:DCIX), (the “Company”), a global shipping company specializing in the ownership of containerships, today reported a net loss of $7.4 million for the...
May 22, 2017 12:36 pm UTC| Business
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study ongoing, with topline data...
May 22, 2017 12:36 pm UTC| Business
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study ongoing, with topline data...
May 22, 2017 12:36 pm UTC| Business
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets -- -- Multi-dose Phase 1b steady state study ongoing, with topline data...